Nivalis Therapeutics Inc. (NVLS) Receives Consensus Rating of “Hold” from Brokerages
Nivalis Therapeutics Inc. (NASDAQ:NVLS) has been given a consensus rating of “Hold” by the seven ratings firms that are covering the company. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $7.42.
Several research analysts have issued reports on the company. Raymond James Financial Inc. cut Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Stifel Nicolaus cut Nivalis Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $16.00 to $3.25 in a research report on Tuesday. Piper Jaffray Cos. restated a “buy” rating and issued a $16.00 price target on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. HC Wainwright restated a “buy” rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Finally, Zacks Investment Research upgraded Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price target for the company in a research report on Thursday, October 20th.
In related news, EVP David Malcom Rodman sold 5,820 shares of the stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total transaction of $46,327.20. Following the sale, the executive vice president now owns 18,056 shares of the company’s stock, valued at $143,725.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.00% of the company’s stock.
Several hedge funds have recently bought and sold shares of NVLS. AXA raised its stake in shares of Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock worth $2,455,000 after buying an additional 139,652 shares during the last quarter. Opaleye Management Inc. raised its stake in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares during the last quarter. BVF Inc. IL raised its stake in shares of Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock worth $8,862,000 after buying an additional 379,700 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Nivalis Therapeutics during the second quarter worth about $105,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the last quarter. 79.26% of the stock is currently owned by institutional investors and hedge funds.
Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded down 59.0416% during mid-day trading on Tuesday, reaching $2.5599. 3,724,921 shares of the company traded hands. Nivalis Therapeutics has a 52-week low of $2.50 and a 52-week high of $9.46. The company’s 50 day moving average is $6.46 and its 200 day moving average is $5.84. The stock’s market capitalization is $39.79 million.
Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. On average, equities analysts forecast that Nivalis Therapeutics will post ($2.10) earnings per share for the current year.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.